Eric Lefkofsky, Founder and CEO of Tempus, shared a post on LinkedIn:
“Pediatric genetic testing for rare disease is now not only in the guidelines but regularly reimbursed by payers. This is good news for families and clinicians.
Ambry Genetics is quickly emerging as a leader in this space. Ambry’s whole exome tests are bringing answers to families – often ending years of uncertainty.”
More posts featuring Eric Lefkofsky.